5-[(2-chlorophenyl)sulfanyl]-2-{6-[(2-cyclopropylethyl)amino]pyridin-2-yl}-6'-[(3,4-difluorophenyl)amino]-4-hydroxy-1,2,3,6-tetrahydro-[2,2'-bipyridin]-6-one

ID: ALA5171701

Chembl Id: CHEMBL5171701

PubChem CID: 168269890

Max Phase: Preclinical

Molecular Formula: C32H28ClF2N5O2S

Molecular Weight: 620.12

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1NC(c2cccc(NCCC3CC3)n2)(c2cccc(Nc3ccc(F)c(F)c3)n2)CC(O)=C1Sc1ccccc1Cl

Standard InChI:  InChI=1S/C32H28ClF2N5O2S/c33-21-5-1-2-6-25(21)43-30-24(41)18-32(40-31(30)42,26-7-3-9-28(38-26)36-16-15-19-11-12-19)27-8-4-10-29(39-27)37-20-13-14-22(34)23(35)17-20/h1-10,13-14,17,19,41H,11-12,15-16,18H2,(H,36,38)(H,37,39)(H,40,42)

Standard InChI Key:  XJPQZHPKRRVQMS-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5171701

    ---

Associated Targets(Human)

LDHA Tchem L-lactate dehydrogenase A chain (1573 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LDHB Tchem L-lactate dehydrogenase B chain (463 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 620.12Molecular Weight (Monoisotopic): 619.1620AlogP: 7.69#Rotatable Bonds: 10
Polar Surface Area: 99.17Molecular Species: ACIDHBA: 7HBD: 4
#RO5 Violations: 2HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 4.89CX Basic pKa: 6.26CX LogP: 5.83CX LogD: 4.87
Aromatic Rings: 4Heavy Atoms: 43QED Weighted: 0.14Np Likeness Score: -1.11

References

1. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE..  (2022)  Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase.,  59  [PMID:35065235] [10.1016/j.bmcl.2022.128576]
2. Wei B, Robarge K, Labadie SS, Chen J, Corson LB, DiPasquale A, Dragovich PS, Eigenbrot C, Evangelista M, Fauber BP, Hitz A, Hong R, Lai KW, Liu W, Ma S, Malek S, O'Brien T, Pang J, Peterson D, Salphati L, Sampath D, Sideris S, Ultsch M, Xu Z, Yen I, Yu D, Yue Q, Zhou A, Purkey HE..  (2022)  Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase.,  59  [PMID:35065235] [10.1016/j.bmcl.2022.128576]

Source